Journal of Harmonized Research in Pharmacy

IN -VIVO ANTI-TUMOUR ACTIVITY OF NOVEL IMIDAZO-[2,1 B]-1,3,4-THIADIAZOLE DERIVATIVES IN EHRLICH ASCITES CARCINOMA AND DALTON?S LYMPHOMA AS CITIES MODEL

Abstract

Author(s): Pallavi K.J., S.V. Satyanarayana, B.S. Tippeswamy

Objective: To study the In-vivo antitumor activity of Novel Imidazo[2,1b]-1,3,4-thiadiazole derivatives on Ehrlich Ascites Carcinoma (EAC) and Dalton Ascites Lymphoma model.(DLA). Materials and Metho ds: The two novel imidazothiadiazole analogues ( Compound 4b, NSC:760239 and Compound 4c, NSC: 760240), in three different concentration were evaluated for their antitumor activity against Ehrlich Ascites Carcinoma (EAC) and two different concentrations were evaluated against Dalton’s ascites lymphoma (DLA), models. In EAC model increase in mean survival time of the drug was measured against control and standard (Levamisole) in mice. Their toxicity was assessed in normal, standard, and EAC bearing mice by measuring the drug induced changes in haematological parameters, In DLA model, the solid tumor volume, solid tumor weight, and % inhibition of the tumor weight of the drug treated over control and standard mice was measured. It is concluded that both the compounds showed dose dependent anticancer activity against control and standard Results: Both the molecules 4b and 4c showed dose dependent anticancer activity against control and standard. The compound 4b was more effective when compared to compound 4c mainly. Conclusion: from the observed results the compound 4b was more effective when compared to compound 4c.